Fluorouracil
- Generic Name
- Fluorouracil
- Brand Names
- Actikerall, Carac, Efudex, Fluoroplex, Tolak
- Drug Type
- Small Molecule
- Chemical Formula
- C4H3FN2O2
- CAS Number
- 51-21-8
- Unique Ingredient Identifier
- U3P01618RT
- Background
A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid.
- Indication
For the topical treatment of multiple actinic or solar keratoses. In the 5% strength it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites. Fluorouracil injection is indicated in the palliative management of some types of cancer, including colon, esophageal, gastric, rectum, breast, biliary tract, stomach, head and neck, cervical, pancreas, renal cell, and carcinoid.
- Associated Conditions
- Actinic Keratosis (AK), Breast Cancer, Colon Cancer, Gastric Cancer, Pancreatic Cancer, Rectal Cancer, Superficial Basal Cell Carcinoma, Verruca (Warts), Hyperkeratotic actinic keratosis
Intraperitoneal Oxaliplatin and Fluorouracil for the Treatment of Patients with Peritoneal Metastases from Colorectal Cancer
- Conditions
- Metastatic Colorectal CarcinomaMetastatic Malignant Neoplasm in the PeritoneumStage IV Colorectal Cancer AJCC V8
- Interventions
- Procedure: BiopsyProcedure: Biospecimen CollectionProcedure: Computed TomographyProcedure: Diagnostic LaparoscopyProcedure: Magnetic Resonance ImagingProcedure: Surgical Procedure
- First Posted Date
- 2024-02-21
- Last Posted Date
- 2025-02-20
- Lead Sponsor
- Arjun Mittra
- Target Recruit Count
- 24
- Registration Number
- NCT06269978
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Botensilimab and Balstilimab Optimization in Colorectal Cancer
- Conditions
- Colorectal Cancer
- Interventions
- First Posted Date
- 2024-02-20
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Nicholas DeVito, MD
- Target Recruit Count
- 15
- Registration Number
- NCT06268015
- Locations
- 🇺🇸
Duke University, Durham, North Carolina, United States
Stereotactic Body Radiation Therapy Followed by NALIRIFOX vs NALIRIFOX for Borderline Resectable Pancreatic Cancer
- Conditions
- Pancreatic Cancer
- Interventions
- First Posted Date
- 2024-02-14
- Last Posted Date
- 2024-03-15
- Target Recruit Count
- 96
- Registration Number
- NCT06259058
Dose Escalation and Expansion Clinical Trial of Irinotecan Liposome Combined With Oxaliplatin and 5-FU/LV Plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- First Posted Date
- 2024-01-26
- Last Posted Date
- 2024-03-19
- Lead Sponsor
- Shanghai Zhongshan Hospital
- Target Recruit Count
- 78
- Registration Number
- NCT06225622
- Locations
- 🇨🇳
Zhongshan Hospital Affiliated to Fudan University, Shanghai, Shanghai, China
AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
- Conditions
- Gastric CancerGastroesophageal Junction CancerBiliary Tract CancerPancreatic Ductal Adenocarcinoma
- Interventions
- First Posted Date
- 2024-01-23
- Last Posted Date
- 2025-05-01
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 190
- Registration Number
- NCT06219941
- Locations
- 🇬🇧
Research Site, Oxford, United Kingdom
Perioperative Treatment in High-risk Resectable Pancreatic Cancer With NALIRIFOX
- Conditions
- Pancreatic Cancer
- Interventions
- First Posted Date
- 2024-01-18
- Last Posted Date
- 2024-01-18
- Lead Sponsor
- Changhai Hospital
- Target Recruit Count
- 134
- Registration Number
- NCT06210360
5-fluorouracil for Treatment of Stable Vitiligo
- First Posted Date
- 2024-01-17
- Last Posted Date
- 2024-04-17
- Lead Sponsor
- Al-Azhar University
- Target Recruit Count
- 40
- Registration Number
- NCT06209138
- Locations
- 🇪🇬
Al-Azhar University, Assiut, No State, Egypt
Phase II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab in Advanced Gastric Cancer
- Conditions
- Gastric Cancer
- Interventions
- First Posted Date
- 2024-01-09
- Last Posted Date
- 2024-01-09
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 36
- Registration Number
- NCT06197438
Liposomal Irinotecan and Leucovorin/5-fluorouracil Plus Bevacizumab in Metastatic Colorectal Cancer
- Conditions
- Colorectal Cancer
- Interventions
- First Posted Date
- 2023-12-28
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- Hebei Medical University Fourth Hospital
- Target Recruit Count
- 173
- Registration Number
- NCT06184698
- Locations
- 🇨🇳
The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China
Safety and Efficacy of Thermosensitive Hydroxybutyl Chitosan and 5-fluorouracil Assisted Endoscopic Dacryocystorhinostomy in the Treatment of Chronic Dacryocystitis
- Conditions
- DacryocystorhinostomyChronic DacryocystitisHydroxybutyl ChitosanFluorouracil
- Interventions
- First Posted Date
- 2023-12-19
- Last Posted Date
- 2023-12-19
- Lead Sponsor
- Tianjin Medical University Eye Hospital
- Target Recruit Count
- 90
- Registration Number
- NCT06175676
- Locations
- 🇨🇳
Limin Zhu, Tianjin, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.